Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infections)
A nosocomial, or hospital-acquired, infection is a new infection that is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, This type of infection is also known as a hospital-acquired infection (or more generically healthcare-associated infections).
Marketing planners in the pharmaceutical or diagnostic industries should have an understanding of the market impact of nosocomial infections, as it will be an important consideration in these markets into the near future.
This report. Hospital Acquired Infections (Nosocomial) : Diagnostic and Pharmaceutical Market Considerations : MRSA, HAP, Cdiff and Other market impact of treating the following infections are discussed in detail:
The Most Recent and Relevant Epidemiological Statistics on HAIs
There is no 'noscomial infection' market per se, it is reflected in sales and revenues of all infectious disease testing and therapeutics. Therefore Kalorama's market analysis in this report considers primarily the epidemiological considerations and the sizes patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital environment in order to try and construct a picture of the nosocomial testing needs.
Estimates of Market Impact
As mentioned above, the primary focus of this report is on the bacterial form of nosocomial infections, and those with significant impact on the hospital setting and markets. In looking at these infections, we consider the diagnostic and therapeutics technologies that are currently available and attempt to project trends in these product areas.
Company Profiles and Competitive Assessment
This report examines the key players in HAI infection diagnostics and pharmaceutical treatement, their revenues, and activity in the market. To some extent, we are limited by the activity of the industries associated with the diagnosis and treatment of these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology. This presages opportunities for new competitors
The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, research scientists, business development managers and marketing managers.
Marketing planners in the pharmaceutical or diagnostic industries should have an understanding of the market impact of nosocomial infections, as it will be an important consideration in these markets into the near future.
This report. Hospital Acquired Infections (Nosocomial) : Diagnostic and Pharmaceutical Market Considerations : MRSA, HAP, Cdiff and Other market impact of treating the following infections are discussed in detail:
- Acinetobacter baumannii
- Clostridium difficile
- Gastroenteritis
- Hospital-acquired pneumonia (HAP) and ventilator associated pneumonia
- Methicillin resistant staphylococcus aureus MRSA
- Pseudomonas aeruginosa
- Staphylococcus aureus
- Stenotrophomonas maltophilia
- Tuberculosis
- Urinary tract infection
- Vancomycin-resistant enterococcus
The Most Recent and Relevant Epidemiological Statistics on HAIs
There is no 'noscomial infection' market per se, it is reflected in sales and revenues of all infectious disease testing and therapeutics. Therefore Kalorama's market analysis in this report considers primarily the epidemiological considerations and the sizes patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital environment in order to try and construct a picture of the nosocomial testing needs.
Estimates of Market Impact
As mentioned above, the primary focus of this report is on the bacterial form of nosocomial infections, and those with significant impact on the hospital setting and markets. In looking at these infections, we consider the diagnostic and therapeutics technologies that are currently available and attempt to project trends in these product areas.
Company Profiles and Competitive Assessment
This report examines the key players in HAI infection diagnostics and pharmaceutical treatement, their revenues, and activity in the market. To some extent, we are limited by the activity of the industries associated with the diagnosis and treatment of these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology. This presages opportunities for new competitors
The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, research scientists, business development managers and marketing managers.
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER TWO: OVERVIEW OF NOSOCOMIAL INFECTIONS
CHAPTER THREE: DRUG-RESISTANT NOSOCOMIAL INFECTIONS
CHAPTER FOUR: EPIDEMIOLOGICAL MARKET CONSIDERATIONS
CHAPTER FIVE: COMPANY SNAPSHOTS
CHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS
- Specific Nosocomial Infections
- Acinetobacter Baumannii
- Clostridium Difficile
- Gastroenteritis
- Hospital-Acquired Pneumonia (HAP)
- Ventilator-Associated Pneumonia (VAP)
- Pseudomonas Aeruginos
- Staphylococcus Aureus/Methicillin-Resistant Staphylococcus Aureus
- Stenotrophomonas Maltophilia
- Tuberculosis
- Urinary Tract Infections
- Vancomycin-Resistant Enterococcus
- Scope and Methodolog
- Market Considerations
- Trends Affecting Nosocomial Infection Applications
CHAPTER TWO: OVERVIEW OF NOSOCOMIAL INFECTIONS
- Overview
- Specific Nosocomial Infections
- Acinetobacter Baumannii
- Clostridium Difficile
- Gastroenteritis
- Hospital-Acquired Pneumonia
- Healthcare-Associated Pneumonia
- Hospital-Acquired Pneumonia
- Ventilator-Associated Pneumonia
- Pseudomonas Aeruginosa
- Staphylococcus Aureus
- Stenotrophomonas maltophilia
- Tuberculosis
- Urinary Tract Infections
CHAPTER THREE: DRUG-RESISTANT NOSOCOMIAL INFECTIONS
- Overview
- Drug-Resistant Acinetobacter
- Drug-Resistant C. Difficile
- Drug-Resistant Enterococci
- Drug-Resistant Pneumonia
- Drug-Resistant Pseudomonas Aeruginosa
- Drug-Resistant Staphylococcus Aureus
- Drug-Resistant Tuberculosis
- Drug-Resistance/Susceptibility Testing
- Genotypic Methods
- DNA Sequencing
- Solid-phase Hybridization Techniques
- Microarrays
- Real-time Polymerase Chain Reaction Techniques
- Phenotypic Method
- Phage-based Assay
- Colorimetric Method
- The Nitrate Reductase Assay
CHAPTER FOUR: EPIDEMIOLOGICAL MARKET CONSIDERATIONS
- Overview
- Acinetobacter Baumannii
- Clostridium Difficile
- Enterococci
- Drug-Resistant Pneumonia
- Pseudomonas aeruginosa
- Staphylococcus aureus
- Drug Resistant Tuberculosis
CHAPTER FIVE: COMPANY SNAPSHOTS
- Abbott Pharmaceuticals (Division of Abbott Laboratories)
- AdvanDx, Inc.
- Becton Dickinson and Company
- Binax, Inc. (Division of Inverness Medical Innovations)
- Cellestis
- Cepheid
- GeneOhm Sciences (Division of Becton Dickinson)
- GlaxoSmithKline plc
- Meridian Bioscience, Inc.
- Merck & Co.
- Schering-Plough
- Techlab, Inc.
- Trek Diagnostics Systems, Ltd. (A Subsidiary of Magellan Biosciences)
- Volu Sol
CHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS
- First Conclusion
- Implications
- Second Conclusion
- Implications
- Third Conclusion
- Implications
- Fourth Conclusion
- Implications
- Fifth Conclusion
- Implications
- Sixth Conclusion
- Implications
- Seventh Conclusion
- Implications
